FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract

BACKGROUND: FGFR2 is a therapy-relevant target in tumors of the upper gastrointestinal tract (GIT), and clinical trials are currently underway to test the efficacy of FGFR2 inhibitors. Tumor heterogeneity is one of the relevant causes of treatment failure. Almost nothing is known about the heterogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Albin, Jan, Fahrig, Luca, Siemanowski, Janna, Rehkaemper, Jan, Gebauer, Florian, Zander, Thomas, Buettner, Reinhard, Bruns, Christiane Josephine, Schroeder, Wolfgang, Alakus, Hakan, Hieggelke, Lena, Quaas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349760/
https://www.ncbi.nlm.nih.gov/pubmed/36416959
http://dx.doi.org/10.1007/s00432-022-04460-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349760/
https://www.ncbi.nlm.nih.gov/pubmed/36416959
http://dx.doi.org/10.1007/s00432-022-04460-w

Ejemplares similares